Strategic Distribution Potential sales opportunity with Semler Scientific, which has a exclusive distribution agreement for Insulin Insights in the United States and Puerto Rico. Engage to align joint go-to-market plans, leverage their channel, and accelerate adoption among clinical sites.

Clinical Validation FDA-cleared and CE-registered software backed by 35 years of published research. Use this to target progressive diabetes clinics seeking evidence-based, regulator-approved decision support to reduce HbA1c and improve safety without increasing hypoglycemia risk.

Market Readiness Works with all eight standard regimens and all insulin types, integrates with glucometers and clinical workflows. Emphasize broad applicability to diverse patient populations and adaptability across existing electronic health record environments to reduce implementation friction.

Growth-Lever Small but scalable organization with recent leadership and board additions. Propose enterprise partnerships, pilot programs at mid-market clinics, and joint marketing to demonstrate impact, building case studies for larger hospital networks.

Financial Upsell Revenue and user base are modest currently (<$1M). Position Insulin Insights as a high-margin, time-saving solution that can expand payer value through improved outcomes and potentially unlock expanded distribution channels via partners in the diabetes care space.